Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-06
2011-12-20
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C514S418000, C514S234500, C514S452000, C514S456000, C514S733000
Reexamination Certificate
active
08080577
ABSTRACT:
The present invention relates to compositions and methods for treating or preventing leiomyomas by administration of diindolylmethane and diindolylmethane-related indoles. The present invention also relates to compositions and methods for treating or preventing leiomyomas by administration of diindolylmethane in combination with an EGFR antagonist. The methods provide non-invasive treatments for leiomyomas.
REFERENCES:
patent: 5635215 (1997-06-01), Boschetti et al.
patent: 5718921 (1998-02-01), Mahtiowitz et al.
patent: 5770599 (1998-06-01), Gibson
patent: 5830887 (1998-11-01), Kelly
patent: 5895787 (1999-04-01), Arffmann et al.
patent: 5948808 (1999-09-01), Safe
patent: 6086915 (2000-07-01), Zeligs et al.
patent: 6399645 (2002-06-01), Bell et al.
patent: 6477229 (2002-11-01), Grosser
patent: 6534085 (2003-03-01), Zeligs
patent: 6613792 (2003-09-01), Ellenberger et al.
patent: 6656963 (2003-12-01), Firestone et al.
patent: 6689387 (2004-02-01), Zeligs
patent: 6800655 (2004-10-01), Jong et al.
patent: 7348352 (2008-03-01), Zeligs
patent: 7384971 (2008-06-01), Zeligs
patent: 7384972 (2008-06-01), Zeligs
patent: 2001/0002393 (2001-05-01), Palmer et al.
patent: 2002/0115708 (2002-08-01), Safe
patent: 2002/0147155 (2002-10-01), Foster et al.
patent: 2003/0096855 (2003-05-01), Zeligs
patent: 2003/0211165 (2003-11-01), Vogel
patent: 2003/0220377 (2003-11-01), Chesworth
patent: 2003/0223956 (2003-12-01), Goupil et al.
patent: 2004/0043965 (2004-03-01), Jong et al.
patent: 2004/0072891 (2004-04-01), Zeligs
patent: 2004/0156910 (2004-08-01), Zeligs
patent: 0566226 (1993-10-01), None
patent: WO 96/30347 (1996-03-01), None
patent: WO 96/33980 (1996-10-01), None
patent: WO 97/02266 (1997-01-01), None
patent: WO 97/30034 (1997-08-01), None
patent: WO 97/38983 (1997-10-01), None
patent: WO 99/55683 (1999-11-01), None
patent: WO 00/31048 (2000-06-01), None
patent: WO 01/20990 (2001-03-01), None
De Leo et al. “A Benefit-Risk Assessment of medical treatment of uterine leiomyomas,” Drug Safety, 2002, vol. 25, No. 11, pp. 760-779.
Akkar et al., 2003, “Formulation of intravenous carbamazepine emulsions by SolEmuls technology,” Eur J. Pharm Biopharm., vol. 55:305-12.
Alberts, B et al., Molecular Biology of the Cell 2nded., 1989, Garland Publishing, Inc., New York, pp. 1193-1194, 1204-1206.
Anjun et al., 1988, “Spontaneous occurrence and experimental induction of leiomyoma of the ventral ligament of the oviduct of the hen,” Res Vet Sci., vol. 45:341-8.
Arbeit, et al., “Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice”, Apr. 1996, Proc Natl Acad Sci, USA 93:2930-2935.
Arici et al., 2003, “Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma,” Am J Obstet Gynecol., vol. 188(1):76-83.
Auborn et al., 2000, “Treatment of Human Papillomavirus Gynecologic Infections”, Clin Lab Med 20:407-22.
Auborn KJ., 2002, “Therapy for recurrent respiratory papillomatosis,” Antiviral Therapy, MTM Publications, London GB., vol. 7(1):1-9.
Baugh SM et al., “Treatment of cervical dysplasia with indole-3-carbinol” in The Ray A. Barlow Scientific Symposium, Jan. 23, 1998, Shreveport : The Center for Excellence in Cancer Research, Treatment and Education, Louisiana State University Medical Center, Shreveport (LA), p. 3.
Bell, MC et al., “Placebo-controlled Trial of Indole-3-Carbinol in the Treatment of Cervical Dysplasia”, Abstracts Presented for the Thirtieth Annual Meeting of the Society of Gynecologic Oncologists Mar. 1999, Gynecol. Oncol. 72, 443-527 (Abstract 13).
Bell, MC et al., “Placebo-Controlled Trial of Indole-3-Carbinol in the Treatment of CIN”, 2000, Gynecologic Oncology, 78:123-129.
Berto et al., 2003, “A comparative analysis of structure and spatial distribution of decorin in human leiomyoma and normal myometrium,” Biochim Biophys Acta., vol. 1619:98-112.
Bioresponse Letter, Dec. 29, 1998.
Bioresponse-DIM Indolplex Product Information Brochure, Dec. 15, 1998.
Bjeldanes et al., 1991, “Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8,-tetrachlorodibenzo-p-dioxin,” Proc. Natl. Acad. Sci. USA 88:9543-9547.
Bradfield et al., “High-performance liquid chromatographic analysis of anticarcinogenic indoles inBrassica oleracea”, 1987, J Agric Food Chem 35:46-49.
Bradfield et al., 1987, “Structure- Activity relationships of dietary indoles: a proposed mechanism of action as modifiers of xenobiotic metabolism,” J Toxicol Environ Health, vol. 21:311-23.
Bradlow et al. “Multifunctional aspects of the action of indole-3-carbinol as an anyi-tumor agent,” Annals of New York Academy of Sciences, 1999, vol. 889, pp. 204-213.
Bradlow et al., “2-hydroxyestrone: the ‘good’ estrogen”, 1996, J Endocrin 150:S259-S265.
Brandi et al., 2003, “A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines,” Cancer Res., vol. 63(14):4028-36.
Buchwald et al., 1980, “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombos,” Surgery, vol. 88:507-16.
Cancer Medicine 3rd edition, 1993, JF Holland ed., Lea & Febiger, Malvern, PA p. 1633.
Chang et al., 1999, “Cytostatic and antiestrogenic effects of 2-(Indo1-3-ylmethyl)-3,3′-diindolylmethane, a major in vivo product of dietary indole-3-carbinol,” Biochem. Pharmacol. 58:825-834.
Chapman et al., 2004, “Expression and deoxyribonucleic acid-binding activity of the nuclear factor kappaB family in the human myomertrium during pregnancy and labor,” J Clin Endocrinol Metab., vol. 89:5683-93.
Chen et al., “Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindoylmethane”, 1998, Carcinogenesis 19:1631-1639.
Chen et al., 2001, “Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium,” J Nutr., vol. 131:3294-302.
Dashwood, R.H., 1998, “Indole-3-carbinol: anticarcinogen or tumor promoter in brassica vegetables?” Chem Biol. Interact., 110(1-2):1-5.
de Kruif et al., 1991, “. Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro,” Chem Biol Interact., vol. 80:803-15.
de Vet et al., 1994, “The role of cigarette smoking in the etiology of cervical dysplasia,” Epidemiology 5:631-633.
During et al., 1989, “Controlled release of dopamine from a polymeric brain implant: in vivo characterization,” Ann Neurol., vol. 25:351-56.
Exon, et al., 2000, “Dietary indole-3-carbinol alters immune functions in rats,” J. Toxicol. Environ. Health A., 59(4):271-9.
Farman, 1975, “Benign smooth muscle tumors,” S. Afr. Med. J., vol. 19:1333-40.
Flake et al., 2003, “Etiology and pathogenesis of uterine leiomyomas: a review,” Environ Health Perspect. vol. 111:1037-54.
Flierman et al., 2005, “Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix,” BJOG., vol. 112:638-42.
Foster et al., 1989, “Influence of selection for increased body weight on the incidence of leiomyomas and leiomyosarcomas in Japanese quail,” Poult Sci., vol. 68:1447-53.
Gao et al., 2002, “Endocrine disruption by indole-3-carbinol and tamoxifen: blockage of ovulation,” Toxicol Appl Pharmacol., vol. 183:179-88.
Gillner et al., 1985, “Interactions of indoles with specific binding sites for 2,3,7,8-tetrachlorodiben
Bioresponse L.L.C.
Jones Day
Wang Shengjun
LandOfFree
Diindolylmethane formulations for the treatment of leiomyomas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diindolylmethane formulations for the treatment of leiomyomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diindolylmethane formulations for the treatment of leiomyomas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298980